CryoPort Launches CryoPort Express(TM) Web Portal

CryoPort Leverages Advanced Web Technologies and Integration With Federal Express(TM)

LAKE FOREST, CA -- (MARKET WIRE) -- 07/15/08 -- CryoPort, Inc. (OTCBB: CYRX) (, a leading supplier of affordable temperature-sensitive shipping solutions for the frozen biopharmaceutical industry, today announced the release of CryoPort Express Portal(TM) 1.0 to select pharmaceutical and biomedical providers for final validation. The development and release of the portal follows an extensive review of existing solutions in the market and development of the portal using the latest Web. 2.0 standards and on demand cloud computing technologies. The result provides a rich, dynamic and highly interactive user experience as well as a highly secure and scalable architecture capable of supporting the planned growth of the company.

"From a business perspective, the design goal for the portal was to provide our customers with a mission critical, time and cost saving shipping solution," said Peter Berry, CEO of CryoPort. "CryoPort has introduced the industry's first pay-per-use shipping solution with no up-front costs to the customer. We are backing it up with an equally innovative user interface that greatly simplifies order-entry, automatically schedules multi-leg shipments, creates shipping labels and export documentation, provides real-time end-to-end tracking of the entire cold chain, and generates alarm notification of shipping delays."

CryoPort's Express Portal is tightly integrated with the Federal Express data center via a real-time B2B Web Service that enables CryoPort to monitor every step of the shipping process. Order processing, validation and scheduling are completed in real-time as the customer enters the order. Once the shipper enters the FedEx system, the CryoPort system will continuously monitor every step of the shipment through the FedEx operational framework. This unprecedented visibility into real-time shipping status information enhances CryoPort's ability to detect and remedy shipping delays before they become costly operational exceptions.

About CryoPort

CryoPort ( develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.


This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Stuart Fine
Carpe DM, Inc.